



REFERENCES

- 1- **Gass J.D.M. (1997):** Stereoscopic atlas of macular diseases, diagnosis and treatment, chapter 1 "normal macula". 4th edition. 1- 18.
- 2- **Yamada E. (1982):** Some structural features of the fovea centralis in the human retina. Arch. Ophthalmol. 82: 151-159.
- 3- **Jack J. Kanski (2007):** Butterworth Heinemann. Clinical ophthalmology. 5th edition. Acquired macular disorders. 17: 627-628.
- 4- **Kolb, Linberg and Fisher (1992):** Neurons of the human retina : A Golgi study, The Journal of Comparative Neurology. 318 : 147-187.
- 5- **Yanoff M. and Duker J.S. (2003):** Ophthalmology (second edition). 101 : 779-785.
- 6- **Rodieck R.W. (1973):** The vertebrate Retina : Principles of structure and function. San Francisco, W.H. Freeman.
- 7- **McDonel J.M.(1994):** Ocular embryology and anatomy. Retina. Ryan SJ schachat AP, Murphy, RP. (ed.) Mosby CO, St. Louis. 5-17.
- 8- **Polyok 1957.**
- 9- **Justice J. and Jr Lehmann R.P. (1976):** Cilioretinal artery. A study based on review of stereo fundus photographs and fluorescein angiographic findings. Arch Ophthalmol. 94 : 1355-1358.
- 10- **Hayreh S.S. (1974):** The choriocapillaris. Graeffes Ophthalmol.192: 165-179.



- 11- **Cogan D.G., Toussaint D. and Kuwabara T. (1961):** Retinal vascular patterns IV. Diabetic retinopathy, Arch ophthalmol. 66 : 366-378.
- 12- **Barber and Lieth (2006):** Glial regulation of blood retinal barrier. Penn state retinal research group.
- 13- **Barber and Lieth (1997):** Agrin accumulates in the brain microvascular basal lamina during development of the blood – brain barrier. Penn state retinal research group. 208: 62-74.
- 14- **Gardner T.W., Lieth E., Bonsall D.J. et al. (1997):** Astrocytes increase barrier properties and ZO-1 expression in cultured retinal capillary endothelial cells. Invest Ophthalmol and Vis Sci. 38: 2423-2427.
- 15- **Doc A., Ramos P., Reis A., Proenca R. and Cunha – Vaz J.G. (1998):** Breakdown of the inner and outer blood retinal barrier in streptozotocin – induced diabetes Exp. Eye Res. 67: 569-575.
- 16- **Pournaras J. and Guy Donatil (2000):** Retinal and choroidal circulation. Principles and practice of ophthalmology. 121: 1804-1819.
- 17- **Neuhaus J., Risau W. and Wolburg H. (1991):** Induction of blood – brain barrier characteristics in bovine – brain endothelial cells by rat astroglial cells in transfilter coculture. Ann NY. Acad. Sci. 633: 578-580.
- 18- **Hogan M.J., Awarads J.A. and Weddel J.E. (1971):** Histology of the human eye Philadelphia. WB Saunders. 369.



- 19- **Bresnik G.H.** Diabetic macular edema: a review. *Ophthalmology*.989-997.
- 20- **Bringmann A., Reichenbach A. and Wiedemann P.(2004):** Pathomechanism of cystoid macular edema. *Ophthalmic Res.* 36:241-249.
- 21- **Witmer A.N., Vrensen G.F., Van Noorden C.J. and Schlingemann R.O. (2003):** Vascular endothelial growth factors and angiogenesis in eye disease. *Prog Retin Eye Res.*22:1-29.
- 22- **Kim W., Hudson B.I., Moser B. et al.(2005):** Receptor for advanced glycation end products and its ligands: a journey from the complications of diabetes to its pathogenesis. *Ann NY Acad Sci.* 1043:553-561.
- 23- **Aiello L.P., Davis M.D., Girach A. et al. (2006):** Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. *Ophthalmology.* 113:2221-2230.
- 24- **Barile G.R., Pachydaki S.I., Tari S.R. et al. (2005):** The RAGE axis in early diabetic retinopathy. *Invest Ophthalmol Vis Sci.* 46:2916-2924.
- 25- **Klein R., Klein B.E.K., Moss S.E. and Cruickshanks K.J.(1995):** The Wisconsin epidemiologic study of diabetic retinopathy. XV. The long term incidence of macular edema. *Ophthalmology.* 102:7-16.
- 26- **Early Treatment Diabetic Retinopathy Study Research Group (1987):** Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. *Early Treatment*



- Diabetic Retinopathy Study Report Number 2. Ophthalmology 94:761-774.
- 27- **Jack J. Kanski (2007):** Butterworth Heinemann. Clinical ophthalmology. 5th edition. Retinal vascular diseases. 16: 572-573.
- 28- **Early Treatment Diabetic Retinopathy Study R.(1985):** Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol. 103:1796-1806.
- 29- **Klein R., Klein B.E., Moss S.E. and Cruickshanks K.J.(1998):** The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14- year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology. 105:1801-1815.
- 30- **Klein R., Meuer S.M., Moss S.E. and Klein B.E. (1995):** Retinal microaneurysm counts and 10-year progression of diabetic retinopathy. Arch Ophthalmol 113:1386-1391.
- 31- **Lopes de Faria J.M., Jalkh A.E., Trempe C.L. and McMeel J.W. (1999):** Diabetic macular edema: risk factors and concomitants. Acta Ophthalmol Scand 77:170-175.
- 32- **Toth C.A., Narayan D.G., Boppart S.A., Hee M.R., Fujimoto J.G., Birngruber R. et al. (1997):** A comparison of retinal morphology viewed by optical coherence tomography and by light microscopy. Arch Ophthalmol 115:1425-1428.



- 33- **Bresnik G.H. (1983):** Diabetic maculopathy; a critical review highlighting diffuse macular edema. *Ophthalmology*. 90: 1301-1317.
- 34- **Meunier I., Soubrane G. and Coscas G. (1995):** [Laser photocoagulation treatment of diabetic maculopathy]. *Bull Soc Belge Ophtalmol*. 256:81-84.
- 35- **Klein R., Klein B.E.K. and Moss S.E.(1991):** The epidemiology of ocular problems in diabetes mellitus. in SS F (ed): *Ocular problems in diabetes mellitus*. Boston, Blackwell Scientific Publications. 1-51.
- 36- **Aroca P.R., Salvat M., Fernandez J. and Mendez I.(2004):** Risk factors for diffuse and focal macular edema. *J Diabetes Complications*. 18:211-215.
- 37- **Miljanovic B., Glynn R.J., Nathan D.M. et al. (2004):** A prospective study of serum lipids and risk of diabetic macular edema in type 1 diabetes. *Diabetes*. 53:2883-2892.
- 38- **Klein R., Klein BEK. and Moss SE. (1984):** The Wisconsin Epidemiologic study of Diabetic Retinopathy. IV: diabetic macular edema. *Ophthalmology*. 91:1464-1474.
- 39- **Sander B., Larsen M., Moldow B. and Lund-Anderson H. (2001):** Diabetic macular edema: Passive and active transport of fluorescein through the blood-retina barrier, *Invest Ophthalmol Vis Sci*. 42: 433-438.
- 40- **Blair N.P., Tso M.O. and Dodge J.T. (1984):** Pathologic studies of the blood-retinal barrier in the spontaneously diabetic rat, *Invest Ophthalmol Vis Sci*. 25: 302-311.



- 41- **Tso M.O., Cunha-Vaz J.G., Shih C.Y. and Jones C.W. (1980):** Clinicopathologic study of blood–retinal barrier in experimental diabetes mellitus, *Arch Ophthalmol.* 98: 2032–2040.
- 42- **Wong H.C., Boulton M., McLeod D. et al. (1988):** Retinal pigment epithelial cells in culture produce retinal vascular mitogens, *Arch Ophthalmol.* 106: 1439–1443.
- 43- **Witmer A.N., Vrensen G.F., Van Noorden C.J. and Schlingemann R.O. (2003):** Vascular endothelial growth factors and angiogenesis in eye disease, *Prog Retin Eye Res.* 22: 1–29.
- 44- **Nishikiori N., Osanai M., Chiba H. et al. (2007):** Glial cell-derived cytokines attenuate the breakdown of vascular integrity in diabetic retinopathy, *Diabetes.* 56: 1333–1340.
- 45- **Vinores S.A., Derevjanik N.L., Ozaki H. et al. (1999):** Cellular mechanisms of blood–retinal barrier dysfunction in macular edema, *Doc Ophthalmol.* 97: 217-228.
- 46- **Gardner T.W., Lieth E., Khin S.A. et al. (1997):** Astrocytes increase barrier properties and ZO-1 expression in retinal vascular endothelial cells, *Invest Ophthalmol Vis Sci.* 38: 2423-2427.
- 47- **Barber A.J. (2003):** A new view of diabetic retinopathy: a neurodegenerative disease of the eye, *Prog Neuropsychopharmacol Biol Psychiatry.* 27: 283-290.
- 48- **Hammes H.P., Lin J., Renner O. et al. (2002):** Pericytes and the pathogenesis of diabetic retinopathy, *Diabetes.* 51: 3107-3112.



- 49- **Dosso A.A., Leuenberger P.M. and Rungger-Brandle E. (1999):** Remodeling of retinal capillaries in the diabetic hypertensive rat, *Invest Ophthalmol Vis Sci.* 40: 2405-2410.
- 50- **Li W., Yanoff M., Liu X. and Ye X. (1997):** Retinal capillary pericyte apoptosis in early human diabetic retinopathy, *Chin Med J (Engl).* 110: 659-663.
- 51- **Joussen A.M., Poulaki V., Le M.L. et al. (2004):** A central role for inflammation in the pathogenesis of diabetic retinopathy, *Faseb J.* 18: 1450-1452.
- 52- **Kaji Y., Usui T. and Ishida S. (2007):** Inhibition of diabetic leukostasis and blood–retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products, *Invest Ophthalmol Vis Sci.* 48: 858-865.
- 53- **Joussen A.M., Murata T., Tsujikawa A. et al. (2001):** Leukocyte-mediated endothelial cell injury and death in the diabetic retina, *Am J Pathol.* 158: 147-152.
- 54- **Miyamoto K., Khosrof S., Bursell S.E. et al. (1999):** Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1inhibition. *Proc Natl Acad Sci USA.* 96:10836-10841.
- 55- **Lu M., Kuroki M., Amano S. et al. (1998):** Advanced glycation end products increase retinal vascular endothelial growth factor expression, *J Clin Invest.* 101: 1219-1224.
- 56- **Kent D., Vinore S.A. and Campochiaro P.A. (2000):** Macular oedema: the role of soluble mediators, *Br J Ophthalmol.* 84: 542-545



- 57- **Mitic L.L. and Anderson J.M. (1998):** Molecular architecture of tight junctions, *Annu Rev Physiol.* 60: 121-142.
- 58- **Antonetti D., Lieth E., Barber A. and Gardner T. (1999):** Molecular mechanisms of vascular permeability in diabetic retinopathy, *Sem Ophthalmol.* 14: 240-248.
- 59- **Antonetti D.A., Barber A.J., Hollinger L.A. et al. (1999):** Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1, *J Biol Chem.* 274: 23463-23467.
- 60- **Erickson K.K., Sandstrom J.M. and Antonetti D.A. (2007):** Vascular permeability in ocular disease and the role of tight junctions, *Angiogenesis.* 10: 103-117.
- 61- **Hou J., Gomes A.S., Paul D.L. and Goddenough D.A. (2006):** Study of claudin function by RNA interference. *J. Biol Chem.* 281: 36117-36123.
- 62- **Landau D. (2006):** Epithelial paracellular proteins in health and disease. *Curr Opin Nephrol Hyperten.* 15:425-429.
- 63- **Schmetterer L., Findl O., Fasching P. et al. (1997):** Nitric oxide and ocular blood flow in patients with IDDM. *Diabetes.* 46: 653-658.
- 64- **Olsson A.K., Dimberg A., Kreuger J. and Claesson-Welsh L. (2006):** VEGF receptor signalling—in control of vascular function. *Nat Rev Mol Cell Biol.* 7:359-371.
- 65- **Williams B., Gallachen B., Patel B. and Orme C. (1997):** Glucose-induced protein kinase C activation regulates vascular permeability



factorm RNA expression and peptide production by vascularsmooth muscle cells in vitro. Diabetes.46:1497-1503.

- 66- **Aiello L.P., Bursell S-E., Clermont A. et al. (1997):** Vascular endothelial growth factor—induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta isoform selective inhibitor. Diabetes.46:1473-1480.
- 67- **Frank R.N., Amin R., Kennedy A. and Hohman T.C. (1997):** An aldosereductase inhibitor and aminoguanidine prevent vascular endothelial growth factor expression in rats with long term galactosemia. Arch Ophthalmol.115:1036-1047.
- 68- **Famiglietti E.V., Stopa E.G., McGookin E.D. et al. (2003):** Immunocytochemical localization of vascular endothelial growth factor in neurons and glial cells of human retina. Brain Res. 969:195-204.
- 69- **Hammes H.P., Lin J., Bretzel R.G. et al. (1998):** Upregulation of the vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat. Diabetes.47:401-406.
- 70- **Shima D.T., Adamis A.P., Ferrara N. et al. (1995):** Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. Mol Med.1:182-193.
- 71- **Antcliff R.J. and Marshall J. (1999):** The pathogenesis of edema in diabetic aculopathy. Semin Ophthalmol.14:223-232.



-
- 72- **Roberts W.G. and Palade G.E. (1995):** Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. *J Cell Sci.*108:2369-2379.
- 73- **Miller E.C., Capps B.E., Sanghani R.R. et al. (2007):** Regulation of α -I signaling in retinal endothelial cells by hyperglycemia. *Invest Ophthalmol Vis Sci.*48:3878-3887.
- 74- **Pfeiffer A., Spranger J., Meyer-Schwickerath R. and Schatz H. (1997):** Growth factor alterations in advanced diabetic retinopathy: a possible role of blood retinal barrier breakdown. *Diabetes.*46:S26-30.
- 75- **Cohen T., Nahari D., Cerem L.W., et al. (1996):** Interleukin 6 induces the expression of vascular endothelial growth factor. *J Biol Chem.* 271:736-741.
- 76- **Funatsu H., Yamashita H., Noma H. et al. (2002):** Increased levels of vascular endothelial growth factor and interleukin- 6 in the aqueous humor of diabetics with macular edema. *Am J Ophthalmol.* 133:70-77.
- 77- **Shimizu E., Funatsu H., Yamashita H. et al. (2002):** Plasma level of interleukin-6 is an indicator for predicting diabetic macular edema. *Jap J Ophthalmol.*46:78-83.
- 78- **Joussen A.M., Poulaki V., Qin W. et al. (2002):** Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. *Am J Pathol.* 160:501-509.



- 79- **Emoto M., Anno T., Sato Y. et al.(2001):** Troglitazone treatment increases plasma vascular endothelial growth factor in diabetic patients and its mRNA in 3T3-L1 adipocytes. *Diabetes*. 50:1166-1170.
- 80- **Zhou X.P., Li C., Dlugosz J. et al. (1994):** Regulation of atypical protein kinase C in cellular signaling. *Exp Cell Res*.
- 81- **Rosson D., O'Brien T.G., Kampherstein J.A. et al. (1997):** Protein kinase C-alpha activity modulates transepithelial permeability and cell junctions in the LLC-PK1 epithelial cell line. *J Biol Chem*. 272:14950-14953.
- 82- **Strom C., Sander B., Klemp K. et al. (2005):** Effect of ruboxistaurin on blood--retinal barrier permeability in relation to severity of leakage in diabetic macular edema. *Invest Ophthalmol Vis Sci*. 46:3855-3858.
- 83- **Inoguchi T., Battan R., Handler E. et al. (1992):** Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. *Proc Natl Acad Sci USA*.89:11059-11063.
- 84- **Shiba T., Inoguchi T., Sportsman J.R. et al. (1993):** Correlation of diacylglycerol and protein kinase C activity in rat retina to retinal circulation. *Am J Physiol*. 265:E783-793.
- 85- **Whiteside C. and Dlugosz J. (2002):** Mesangial cell protein kinase C isozyme activation in diabetic milieu. *Am J Physiol Renal Physiol*. 282:F975-980.



-
- 86- **Chakrabarti S. and Sima A.A.F. (1997):** Endothelin 1 and endothelin 3 like immunoreactivity in the eyes of diabetic and non-diabetic BB/W rats. *Diabetes Res Clin Pract.*37:109-120.
- 87- **Kawamura H., Oku H., Li Q. et al. (2002):** Endothelin-induced changes in the physiology of retinal pericytes. *Invest Ophthalmol Vis Sci.*43:882-888.
- 88- **McGinty A., Scholfield C.N., Liu W-H. et al. (1999):** Effect of glucose on endothelin 1induced calcium transients in cultured bovine retinal pericytes. *J Biol Chem.*274:25250-25253.
- 89- **Takagi C., Bursell S-E., Lin Y-W. et al. (1996):** Regulation of retinal hemodynamics in diabetic rats by increased expression and action of endothelin-1. *Invest Ophthalmol Vis Sci.*37: 2504-2518.
- 90- **Gill D.S., Barradas M.A., Fonseca V.A. and Dandona P. (1989):** Plasma histamine concentrations are elevated in patients with diabetes mellitus and peripheral vascular disease. *Metabolism.* 38:243-247.
- 91- **Gardner T. (1995):** Histamine, ZO-1 and increased blood retinal permeability in diabetic retinopathy. *Trans Am Ophthalmol Soc.*93:583-621.
- 92- **Berka J.L., Stubbs A.J., Wang D.Z. et al. (1995):** Renin-containing Muller cells of the retina display endocrine features. *Invest Ophthalmol Vis Sci.*36:1450-1458.
- 93- **Danser A.H., Derkx F.H., Admiraal P.J. et al. (1994):** Angiotensin levels in the eye. *Invest Ophthlmol Vis Sci.*35:1008-1018.
-



-
- 94- **Estacio R.O., Jeffers B.W., Hiatt W.R. et al. (1998):** The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. *N Engl J Med.*338: 645-652.
- 95- **Chua C.C., Hamdy R.C. and Chua B.H. (1998):** Upregulation of vascular endothelial growth factor by angiotensin II in rat heart endothelial cells. *Biochem Biophys Acta.* 1401:187-194.
- 96- **Williams B., Baker A.Q., Gallacher B. and Lodwick D. (1995):** Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells. *Hypertension.* 25:913-917.
- 97- **Cunha-Vaz J.G., Shakib M. and Ashton N. (1966):** Studies on the permeability of the blood–retinal barrier. I. On the existence, development and site of blood-retinal barrier, *Br J Ophthalmol.* **50**: 441-453.
- 98- **Jin M., Kashiwagi K., Iizuka Y., et al. (2001):** Matrix metalloproteinases in human diabetic and nondiabetic vitreous. *Retina.*21:28-31.
- 99- **Abu A.L., Asrar A.M., Dralands L., Veckeneer M. et al. (1998):** Gelatinase-B in proliferative vitreoretinal disorders. *Am J Ophthalmol.* 125:844-851.
- 100- **Das A., McGuire P.G., Eriqat C. et al. (1999):** Human diabetic neovascular membranes contain high levels of urokinase and metalloproteinase enzymes. *Invest Ophthalmol Vis Sci.*40:809-813.



- 101- ***Spranger J., Osterhoff M., Reimann M. et al. (2001):*** Loss of the antiangiogenic pigment epithelium-derived factor in patients with angiogenic eye disease. *Diabetes*.50: 2641-2645.
- 102- ***Funatsu H., Yamashita H., Nakamura S. et al. (2006):*** Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macular edema. *Ophthalmology*. 113: 294-301.
- 103- ***Ogata N., Ando A., Uyama M. and Matsumura M. (2001):*** Expression of cytokines and transcription factors in photocoagulated human retinal pigment epithelial cells. *Graefes Arch Clin Exp Ophthalmol*. 239:87-95.
- 104- ***Gao G., Li Y., Zhang D. et al. (2001):*** Unbalanced expression of VEGF and PEDF in ischemia-induced retinal neovascularization. *FEBS Lett*. 489: 270-276.
- 105- ***Pendergast S.D., Hassan T.S., Williams G.A. et al. (2000):*** Vitrectomy for diffuse diabetic macular edema associated with a taut premacular posterior hyaloid. *AmJOphthalmol*. 130:178-186.
- 106- ***Li W., Yanoff M., Liu X. and Ye X. (1997):*** Retinal capillary pericyte apoptosis in early human diabetic retinopathy. *Chin Med J (Engl)*. 110:659-663.
- 107- ***Montesano R., Vassalli J.D., Baird A. et al. (1986):*** Basic fibroblast growth factor induces angiogenesis in vitro. *Proc Natl Acad Sci USA*. 83: 7297-72301.



- 108- **McNeil P.L., Muthukrishnan L., Warder E. and D'Amore P.A. (1989):** Growth factors are released by mechanically wounded endothelial cells. *J Cell Biol.*109:811-822.
- 109- **Harada T., Harada C., Kohsaka S. et al. (2002):** Microglia-Muller glial cell interactions control neurotrophic factor production during light-induced retinal degeneration. *J Neurosci.* 22:9228-9236.
- 110- **Sakamoto T. (2003):** [Cell biology of hyalocytes]. *Nippon Ganka Gakkai Zasshi.* 107:866-882, discussion 883.
- 111- **Harbour J.W., Smiddy W.E., Flynn H.W.J. and Rubsamen P.E. (1996):** Vitrectomy for diabetic macular edema associated with a thickened and taut posterior hyaloid membrane. *Am J Ophthalmol.* 121:405-413.
- 112- **Sebag J. and Balazs E.A.(1984):** Pathogenesis of cystoid macular edema: an anatomic consideration of vitreoretinal adhesions. *Surv Ophthalmol.* 28:493-498.
- 113- **Ulbig M.W., McHugh D.A. and Hamilton A.M. (1995):** Diode laser photocoagulation for diabetic macular oedema. *Br J Ophthalmol.* 79:318-321.
- 114- **Hikichi T., Fujio N., Akiba J. et al.(1997):** Association between the short-term natural history of diabetic macular edema and the vitreomacular relationship in type II diabetes mellitus. *Ophthalmology.*104:473-478.
- 115- **Kakehashi A., Schepens C.L. and Trempe C.L. (1994):** Vitreomacular observations: I. Vitreomacular adhesion and hole in the premacular hyaloid. *Ophthalmology.*101: 1515-1521.



- 116- **Holekamp N.M., Shui Y.B. and Beebe D.C. (2005):** Vitrectomy surgery increases oxygen exposure to the lens: a possible mechanism for nuclear cataract formation. *Am J Ophthalmol.* 139:302-310.
- 117- **Sebag J., Buckingham B., Charles M.A. and Reiser K. (1992):** Biochemical abnormalities in vitreous of humans with proliferative diabetic retinopathy. *Arch Ophthalmol.* 110:1472-1476.
- 118- **Jumper J.M., Embabi S.N., Toth C.A. et al.(2000):** Electron immunocytochemical analysis of posterior hyaloid associated with diabetic macular edema. *Retina.* 20:63-68.
- 119- **Kishi S. and Shimizu K. (1990):** Posterior precortical vitreous pocket.[see comments]. *Arch Ophthalmol.* 108:979-982.
- 120- **Massin P., Erginay A., Haouchine B.J. et al. (2002):** Retinal thickness in healthy and diabetic subjects measured using optical coherence tomography mapping software. *Eur J Ophthalmol.* 12:102-108.
- 121- **Schneeberger S.A., Hjelmeland L.M., Tucker R.P. and Morse L.S. (1997):** Vascular endothelial growth factor and fibroblast growth factor 5 are colocalized in vascular and avascular epiretinal membranes. *Am J Ophthalmol.* 124:447-454.
- 122- **Cordon-Cardo C., Vlodavsky I., Haimovitz-Friedman A. et al. (1990):** Expression of basic fibroblast growth factor in normal human tissues. *Lab Invest.* 63:832-840.
- 123- **Kimura T., Kiryu J., Nishiwaki H. et al. (2005):** Efficacy of surgical removal of the internal limiting membrane in diabetic cystoid macular edema. *Retina.* 25:454-461.



- 124- **Rosenblatt B.J., Shah G.K., Sharma S. and Bakal J. (2005):** Pars plana vitrectomy with internal limiting membranectomy for refractory diabetic macular edema without a taut posterior hyaloid. Graefes Arch Clin Exp Ophthalmol. 243:282.
- 125- **Yamamoto T., Akabane N. and Takeuchi S. (2001):** Vitrectomy for diabetic macular edema: The role of posterior detachment and epimacular membrane. Am J Ophthalmol. 132:369-377.
- 126- **Stefansson E. (2001):** The therapeutic effects of retinal laser treatment and vitrectomy. A theory based on oxygen and vascular physiology. Acta Ophthalmol Scand. 79: 435-440.
- 127- **Nguyen Q.D., Shah S.M., Van Anden E. et al. (2004):** Supplemental oxygen improves diabetic macular edema: a pilot study. Invest Ophthalmol Vis Sci. 45:617-624.
- 128- **McMillan D.E. (1976):** Plasma protein changes, blood viscosity, and diabetic microangiopathy. Diabetes. 25:858-864.
- 129- **Sakata K., Funatsu H., Harino S. et al. (2006):** Relationship between macular microcirculation and progression of diabetic macular edema. Ophthalmology. 113:1385-1391.
- 130- **Browning D.J., McOwen M.D., Bowen R.M. and Jr O'Marah T.L. (2004):** Comparison of the clinical diagnosis of diabetic macular edema with diagnosis by optical coherence tomography. Ophthalmology. 111:712-715.
- 131- **Puliafito C.A., Hee M.R., Lin C.P. et al. (1995):** Imaging of macular diseases with optical coherence tomography. Ophthalmology. 102:217-229.



- 132- **Pavlin C.J., Harasiewicz K., Sherar M.D. and Foster F.S.(1991):** Clinical use of ultrasound biomicroscopy. *Ophthalmology*.98: 287-295.
- 133- **Bille J.F., Dreher G.W. and Zinser G. (1990):** Scanning laser tomography of the living human eye. in Masters BR (ed): *Noninvasive Diagnostic Techniques in Ophthalmology*. New York: Springer-Verlag. 528-547.
- 134- **Kang S.W., Park C.Y. and Ham D.I. (2004):** The correlation between fluorescein angiographic and optical coherence tomographic features in clinically significant diabetic macular edema. *American Journal of Ophthalmology*.137: 313-322.
- 135- **Scanlon P.H., Wiltinson C.P., Aldington S.J. and Matthews DR. (2008):** A practical Mannual of diabetic retinopathy management. *Maculopathy*. 6: 70-74.
- 136- **Conrath J., Giorgi R., Raccach D. and Ridings B. (2005):** Foveal vascular zone in diabetic retinopathy: quantitative vs. qualitative assessment. *Eye*. 19:322-326.
- 137- **Strom C., Sander B., Larsen N. et al. (2002):** Diabetic macular stereo fundus photography. *Invest Ophthalmol Vis Sci*. 43: 241-245.
- 138- **Otani T., Kishi S. and Maruyama Y. (1999):** Patterns of diabetic macular edema with optical coherence tomography. *Am J Ophthalmol*. 127:688-693.
- 139- **Chan A. and Duker J.S. (2005):** A standartized method for reporting changes in macular thickening using optical coherence tomography. *Arch Ophthalmol*. 123:939-943.



- 140- **Gaucher D., Tadayoni R., Erginay A. et al.(2005):** Optical coherence tomography assessment of the vitreoretinal relationship in diabetic macular edema. *Am J Ophthalmol.* 139:807-813.
- 141- **Jaffe G.J. and Caprioli J.(2004):** Optical coherence tomography to detect and manage retinal disease and glaucoma. *Am J Ophthalmol.* 137:156-169.
- 142- **Holz F.G., Spaide R.F. (2010):** Medical retina. Focus on retinal imaging. Investigation of Diagnostic Accuracy of OCT for detection of DME. 12:135.
- 143- **Scanlon P.H., Wiltinson C.P., Aldington S.J. and Matthews D.R. (2008):** A practical manual of diabetic retinopathy management. Introduction. 1: 7.
- 144- **Otani T., Tishi S. and Maruyama, Y. (1999):** Patterns of diabetic macular edema with optical coherence tomography. *Am. J. Ophthalmol* 127: 688-693.
- 145- **Wolf-Schnurrbusch U.E., Ceklic L., Brinkmann C.K., et al., (2009):** Macular thickness measurements in healthy eyes using six different optical coherence tomography instruments. *Invest Ophthalmol Vis. Sci.* 50:3432-3437.
- 146- **Holz F.G., Spaide R.F. (2010):** Medical retina. Focus on retinal imaging. Assessing Diabetic Macular Edema with optical coherence tomography. 11: 126-127.
- 147- **Konno S., Akiba J. and Yoshida A.(2001):** Retinal thickness measurements with optical coherence tomography and the scanning retinal thickness analyzer. *Retina.*21:57-61.



- 148- **Asrani S., Zou S., D'anna S. et al.(1999):** Noninvasive mapping of the normal retinal thickness at the posterior pole. *Ophthalmology*. 106: 269-273.
- 149- **Polito A., Shah S.M., Haller J.A., et al. (2002):** Comparison between retinal thickness analyzer and optical coherence tomography for assessment of foveal thickness in eyes with macular disease. *Am J Ophthalmol*. 134:240-251.
- 150- **Degenring R.F., Aschmoneit I., Kamppeter B. et al.(2004):** Optical coherence tomography and confocal scanning laser tomography for assessment of macular edema. *Am J Ophthalmol*. 138:354-361.
- 151- **Browning D.J., McOwen M.D., Bowen R.M. and Jr O'Marah T.L. (2004):** Comparison of the clinical diagnosis of diabetic macular edema with diagnosis by optical coherence tomography. *Ophthalmology*. 111:712-715.
- 152- **Apple D.J., Goldberg M.F. and Wyhinny G. (1973):** Histopathology and ultrastructure of the argon laser lesion in human retinal and choroidal vasculatures. *Am J Ophthalmol*. 75: 595-609.
- 153- **Stefansson E., Hatchell D.L., Fisher B.L. et al. (1986):** Panretinal photocoagulation and retinal oxygenation in normal diabetic cats. *Am J Ophthalmol*. 101:657-664.
- 154- **Wilson D.J. and Green R.W. (1987):** Argon laser panretinal photocoagulation for diabetic retinopathy. Scanning electron microscopy of human choroidal vascular casts. *Arch Ophthalmol*. 105:239-242.



- 155- **Wilson D.J., Finkelstein D., Quigley H.A. and Green R.W.(1988):** Macular grid photocoagulation. An experimental study on the primate retina. Arch Ophthalmol. 106:100-105.
- 156- **Gottfredsdottir M.S., Stefansson E., Jonasson F. and Gislason I.(1993):** Retinal vasoconstriction after laser treatment for diabetic macular edema. Am J Ophthalmol. 115: 64-67.
- 157- **Boulton M.E., Xiao M. and Khaliq A. (1995):** Changes in growth factor expression in pig eyes following scatter laser photocoagulation. Invest Ophthalmol Vis Sci. 36:95.
- 158- **Guyer D.R., D'Amico D.J. and Smith C.W.(1992):** Subretinal fibrosis after laser photocoagulation for diabetic macular edema. Am J Ophthalmol. 113:652-656.
- 159- **Roider J., Michaud N., Flotte T. and Birngruber R. (1992):** Response of the RPE to selective photocoagulation of the RPE by repetitive short laser pulses. Arch Ophthalmol. 110: 1786-1792.
- 160- **Spalter H.F. (1971):** Photocoagulation of circinate maculopathy in diabetic retinopathy. Am J. Ophthalmol. 1: 242-250.
- 161- **Whitelocke R.A., Kearns M., Blach R.K. and Hamilton A.M. (1979):** The diabetic maculopathies. Trans Ophthalmol Soc UK. 99: 314-320.
- 162- **Photocoagulation for diabetic maculopathy (1983):** A randomized controlled clinical trial using the xenon arc. British Multicentre Study Group. Diabetes. 32: 1010-1016.
- 163- **Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial (1998):** Arch Ophthalmol. 116: 874-886.



- 164- **Bailey C.C., Sparrow J.M., Grey R.H. and Cheng H. (1999):** The National Diabetic Retinopathy Laser Treatment Audit. III. Clinical outcomes. *Eye*. 13: 151-159.
- 165- **The Diabetic Retinopathy Study Research Group (1981):** Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. *Ophthalmology*. 88: 583-600.
- 166- **Early Treatment Diabetic Retinopathy Study R.(1991):** Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. *Ophthalmology*. 98:766-785.
- 167- **Gangnon R., Hubbard L.D., Aiello L.M., Chew E.Y., Ferris F.L., Fisher M.R. et al. (2008):** A severity scale for diabetic macular edema developed from ETDRS data. *Invest Ophthalmol Vis Sci*. 49:5041-5047.
- 168- **Lee C.M. and Olk R.J. (1991):** Modified grid laser photocoagulation for diffuse diabetic macular edema. Long-term visual results. *Ophthalmology*. 98:1594-1602.
- 169- **Early Treatment Diabetic Retinopathy Study Research Group (1991):** Early photocoagulation for diabetic retinopathy ETDRS report number 9. *Ophthalmology*. 98: 766-785.
- 170- **Nonaka A., Kiryu J., Tsujikawa A., Yamashiro K., Nishijima K., Kamizuru H. et al. (2002):** Inflammatory response after scatter laser photocoagulation in nonphotocoagulated retina. *Invest Ophthalmol Vis Sci*. 43: 1204-1209.



- 171- **Blankenship G. (1988):** A clinical comparison of central and peripheral argon laser panretinal photocoagulation for proliferative diabetic retinopathy. *Ophthalmology*. 95:170-177.
- 172- **Rutledge B.K., Wallow I.H. and Poulsen G.L.(1993):** Sub-pigment epithelial membranes after photocoagulation for diabetic macular edema. *Arch Ophthalmol*. 111:608-613.
- 173- **Stefansson E. (2006):** Ocular oxygenation and the treatment of diabetic retinopathy. *Surv Ophthalmol*. 51:364-380.
- 174- **Kadonosono K., Itoh N. and Ohno S. (2000):** Perifoveal microcirculation before and after vitrectomy for diabetic cystoid macular edema. *Am J Ophthalmol*. 130:740-744.
- 175- **Kaiser P.K., Riemann C.D., Sears J.E. and Lewis H. (2001):** Macular traction detachment and diabetic macular edema associated with posterior hyaloidal traction. *Am J Ophthalmol*. 131:44-49.
- 176- **Grigorian R., Bhagat N., Lanzetta P. et al. (2003):** Pars plana vitrectomy for refractory diabetic macular edema. *Semin Ophthalmol*. 18: 116-120.
- 177- **La Heij E.C., Hendrikse F., Kessels A.G. and Derhaag P.J.(2001):** Vitrectomy results in diabetic macular oedema without evident vitreomacular traction. *Graefes Arch Clin Exp Ophthalmol*. 239:264-270.
- 178- **Tachi N. and Ogino N. (1996):** Vitrectomy for diffuse macular edema in cases of diabetic retinopathy. *AmJOphthalmol*. 8:258-260.
- 179- **Lewis H., Abrams G.W., Blumenkranz M.S. and Campo R.V.(1992):** Vitrectomy for diabetic macular traction and edema



- associated with posterior hyaloidal traction. *Ophthalmology*. 99:753-759.
- 180- ***Ikeda T., Sato K., Katano T. and Hayashi Y. (1999):*** Vitrectomy for cystoid macular oedema with attached posterior hyaloid membrane in patients with diabetes. *Br J Ophthalmol*. 83:12-14.
- 181- ***Pendergast S.D., Hassan T.S., Williams G.A. et al.(2000):*** Vitrectomy for diffuse diabetic macular edema associated with a taut premacular posterior hyaloid. *AmJ Ophthalmol*. 130:178-186.
- 182- ***Otani T. and Kishi S.(2000):*** Tomographic assessment of vitreous surgery for diabetic macular edema. *Am J Ophthalmol*. 129:487-494.
- 183- ***Yang C.M. (2000):*** Surgical treatment for severe diabetic macular edema with massive hard exudates. *Retina*. 20:121-125.
- 184- ***Gandorfer A., Messmer E.M., Ulbig M.W. and Kampik A.(2000):*** Resolution of diabetic macular edema after surgical removal of the posterior hyaloid and the inner limiting membrane. *Retina*. 20:126-133.
- 185- ***Otani T. and Kishi S. (2002):*** A controlled study of vitrectomy for diabetic macular edema. *Am J Ophthalmol*. 134: 214-219.
- 186- ***Brancato R., Patresi R., Leoni G. et al. (1989):*** Retinal photocoagulation with diode laser operating from a slit lamp microscope. *Lasers Light Ophthalmol*. 2:73-78.
- 187- ***Ulbig M.R., Arden G.B. and Hamilton A.M. (1994):*** Color contrast sensitivity and pattern electroretinographic findings after



- diode and argon laser photocoagulation in diabetic retinopathy. *Am J Ophthalmol.* 117:583-588.
- 188- **Micelli Ferrari T., Cardascia N., Durante G. et al. (1999):** Pars plana vitrectomy in diabetic macular edema. *Doc Ophthalmol.* 97:471-474.
- 189- **Akduman L. and Olk R.J.(1997):** Diode laser (810nm) versus argon green (514nm) modified grid photocoagulation for diffuse diabetic macular edema. *Ophthalmology.* 104:1433-1441.
- 190- **Friberg T.R. and Karatza E.C.(1997):** The treatment of macular disease using a micropulsed and continuous wave 810-nm diode laser. *Ophthalmology.* 104:2030-2038.
- 191- **Stanga P.E., Reck A.C. and Hamilton A.M.P.(1999):** Micropulse laser in the treatment of diabetic macular edema. *Semin Ophthalmol.* 14:210-213.
- 192- **Bhagat N. and Zarbin M.A.(2002):** Diode subthreshold laser for DME: Researchers are assessing this laser option as an alternative to photocoagulation for diabetic macular edema. *Rev Ophthalmol.* 9:83-89.
- 193- **Nauck M., Karakiulakis G., Perruchoud A.P. et al. (1998):** Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. *Eur J Pharmacol.* 341:309-315.
- 194- **Bakri S.J. and Kaiser P.K. (2005):** Posterior subtenon triamcinolone acetate for refractory diabetic macular edema, *Am J Ophthalmol.* 139: 290-294.



- 195- **Chew E., Strauber S., Beck R. et al. (2007):** Randomized trial of peribulbar triamcinolone acetonide with and without focal photocoagulation for mild diabetic macular edema: a pilot study. *Ophthalmology*. 114:1190-1196.
- 196- **Jost B.J., Jochen K.H., Antje S. and Songhomitra P. (2001):** Intravitreal injection of Crystalline cortisone as Adjunctive treatment of proliferative diabetic retinopathy, *Am. J. Ophthalmol.* 131:468-471.
- 197- **Michael Ip., Paul A. and Jay S. (1999):** Posterior segment drug delivery vitreoretinal disease the essentials. 37.
- 198- **Vinores S.A., Derevjanik N.L., Ozaki H. et al., (1999):** Cellular mechanisms of blood-retinal barrier dysfunction in macular edema. *Doc Ophthalmol.* 97: 217-228.
- 199- **Kang S.W., Sa H.S., Cho H.Y. and Kim J.I.(2006):** Macular grid photocoagulation after intravitreal triamcinolone acetonide for diffuse diabetic macular edema. *Arch Ophthalmol.* 124:653-658.
- 200- **Antcliff R.J., Spalton D.J., Stanford M.R. et al.(2001):** Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. *Ophthalmology*. 108: 765-772.
- 201- **Spaide R.F., Sorenson J. and Maranan L. (2005):** Combined photodynamic therapy and intravitreal triamcinolone for nonsubfoveal choroidal neovascularization. *Retina*. 25:685-690.
- 202- **Vasconcelos-Santos D.V., Nehemy P.G., Schachat A.P. and Nehemy M.B. (2008):** Secondary ocular hypertension after



intravitreal injection of 4 mg of triamcinolone acetonide: incidence and risk factors. *Retina*. 28:573–580.

203- **Martidis A., Duker J.S., Greenberg P.B. et al.(2002):** Intravitreal triamcinolone for refractory diabetic macular edema. *Ophthalmology*. 109:920-927.

204- **Personal communication with Dr. Tamer Fahmy Mohammed Eliwa. A study by Ain Shams University and Association Retinal Consultants' Clinic, William Beaumont Hospital, Royal Oak, Michigan, USA. (2006):** Comparative study between laser photocoagulation in the treatment of refractory diabetic macular edema.

205- **Furlani B.A., Meyer C.H., Rodrigues E.B. et al. (2007):** Emerging pharmacotherapies for diabetic macular edema. *Expert Opin Emerg Drugs*. 12: 591-603.

206- **Ozaki H., Seo M.S., Ozaki K. et al. (2000):** Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. *Am. J Pathol*. 156:697-707.

207- **Aiello L.P., Bursell S.E. and Devris T. (1999):** Protein kinase C beta selective inhibitor LY333531 ameliorates abnormal retinal hemodynamics in patients with diabetes. *Diabetes* 48: A19.

208- **PKC-DMES (Protein Kinase C β Inhibitor Diabetic Macular Edema Study Group) (2007):** Effect of ruboxistaurin in patients with diabetic macular edema: thirty-month results of the randomized PKC-DMES clinical trial *Archives of Ophthalmology*. 125: 318-324.



- 209- **Tranos P.G., Sanjeewa S.W., Nikos T.S. et al. (2004):** Macular edema. *Surv Ophthalmol* 49:470-490.
- 210- **Simmons E.P. and Foster C.S. (2007):** Diabetic Retinopathy and Macular Edema. *Contemporary Ophthalmology*. 1-8.
- 211- **Chun D.W., Heier J.S., Topping T.M. et al. (2006):** A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. *Ophthalmology*. 113:1706-1712.
- 212- **Macugen Diabetic Retinopathy Study Group (2005):** A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. *Ophthalmology*. 112:1747-1757.
- 213- **Arevalo J.F., Jans F.J., Hugo Q.M. et al. (2007):** Primary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema. *Ophthalmology* 114:743-750.
- 214- **Spaide R.F. and Fisher Y.L. (2006):** Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. 26: 275-278.
- 215- **Kumar A. and Sinha S.(2007):** Intravitreal bevacizumab (Avastin) treatment of diffuse diabetic macular edema in an Indian population. *Indian J Ophthalmol*. 55: 451-455.
- 216- **Yanyali A., Aytug B., Horozoglu F. and Nohutcu A.F. (2007):** Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes. *Am J Ophthalmol*. 1444: 124-126.



- 217- **Haritoglou C., Koik D., Neubauer A., Wolf A., Priglinger S., Strauss R. et al. (2006):** Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. *Retina*.26: 999-1005.
- 218- **Kook D., Wolf A., Kreutzer T. et al., (2009):** Long-term effect of intravitreal bevacizumab (Avastin) in patients with chronic diffuse diabetic macular edema. *Retina*. 28:1053-1060.
- 219- **Roh M.I., Byeon S.H. and Kwon O.W. (2008):** Repeated intravitreal injection of bevacizumab for clinically significant diabetic macular edema. *Retina*. 28: 1314-1318.
- 220- **Macugen Diabetic Retinopathy Study Group. (2006):** Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. *Ophthalmology*. 113: 23-28.
- 221- **Velez-Montoya E., Fromow-Guerra J., Burgos O. et al., (2009):** The effect of unilateral intravitreal bevacizumab (Avastin) in the treatment of diffuse bilateral diabetic macular edema. A pilot study. *Retina*. 29: 20-26.
- 222- **Lam D.S.C, Lai T.Y.Y., Lee V.Y.W. et al., (2009):** Efficacy of 1.25mg versus 2.5mg intravitreal bevacizumab for diabetic macular edema. Six month results of a randomized controlled trial. *Retina*. 29: 292-299.
- 223- **Chase H.P., Garg S.K., Harris S. et al.(1993):** Angiotensin converting enzyme inhibitor treatment for young normotensive diabetic subjects: a two-year trial. *Ann Ophthalmol*. 25:284-289.
- 224- **Giardino I., Fard A.K., Hatchell D.L. and Brownlee M. (1998):** Aminoguanidine inhibits reactive oxygen species formation, lipid



peroxidation and oxidant-induced apoptosis. Diabetes. 47:1114-1120.

- 225- **Agardh C.D., Stenram U., Toffvit O. and Agardh E.(2002):** Effects of inhibition of glycation and oxidative stress on the development of diabetic nephropathy in rats. J Diabetes Complications. 16:395-400.
- 226- **Taguchi T., Sugiura M., Hamada Y. and Miwa I.(1998):** In vitro formation of a Schiff base of aminoguanidine with pyridoxal phosphate. Biochem Pharmacol. 55:1661-1667.
- 227- **Chen A.S., Taguchi T., Sugiura M. et al.(2004):** Pyridoxal aminoguanidine adduct is more effective than aminoguanidine in preventing neuropathy and cataract in diabetic rats. Horm Metab Res. 36:183-187.